Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review.

Autor:	Kapadia RK; Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.; Division of Neurology, Department of Clinical Neurosciences, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada., Staples JE; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Gill CM; University of Iowa, Carver College of Medicine, Department of Neurology, Iowa City, Iowa, USA., Fischer M; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Khan E; Hunterdon Infectious Disease Specialists, Flemington, New Jersey, USA., Laven JJ; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Panella A; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Velez JO; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Hughes HR; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Brault A; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA., Pastula DM; Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.; Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA., Gould CV; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Mar 21; Vol. 76 (6), pp. 1142-1148.
DOI:	10.1093/cid/ciac766
Abstrakt:	With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Centers for Disease Control and Prevention. We identified 21 patients on recent rituximab therapy who were diagnosed with an arboviral disease caused by West Nile, tick-borne encephalitis, eastern equine encephalitis, Cache Valley, Jamestown Canyon, and Powassan viruses. All reported patients had neuroinvasive disease. The diagnosis of arboviral infection required molecular testing in 20 (95%) patients. Median illness duration was 36 days (range, 12 days to 1 year), and 15/19 (79%) patients died from their illness. Patients on rituximab with arboviral disease can have a severe or prolonged course with an absence of serologic response. Patients should be counseled about mosquito and tick bite prevention when receiving rituximab and other B-cell depleting therapies. Competing Interests: Potential conflicts of interest. D. P. reports lecture honorarium from American Academy of Neurology. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu